PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. Its lead product candidates comprise PGN-EDO51, an EDO peptide which is Phase 2 clinical trial to treat duchenne muscular dystrophy (DMD) patients that are amenable to an exon 51-skipping approach; PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and PGN-EDO53, which is in preclinical trial to treat duchenne muscular dystrophy. The company was founded in 2018 and is based in Boston, Massachusetts.

PepGen Inc.

Bank of America Securities analyst Tazeen Ahmad reiterated a Sell rating on PepGen Inc. yesterday and set a price target of $3.00. The company’s sh...

PepGen Inc. (PEPG) Gets a Sell from Bank of America Securities

H.C. Wainwright analyst Ananda Ghosh reiterated a Buy rating on PepGen Inc. today and set a price target of $20.00. According to TipRanks, Ghosh is...

H.C. Wainwright Keeps Their Buy Rating on PepGen Inc. (PEPG)

PepGen Inc. ( ($PEPG) ) has issued an update. On November 4, 2025, PepGen Inc.‘s Board of Directors approved a repricing of underwater stock option...

Market Cap	$149.24M	P/E Ratio	N/A
52W High	$6.85	52W Low	$0.88
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	N/A	52W Position	78.4%
Overall Score	70	Value Score	60
Quality Score	--	Technical Score	81

EPS Current Est	$-2.22	EPS Next Est	$-1.85
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	PEPG	$5.56	+9.23%	1.84M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	PEPG	$5.56	+9.2%	1.84M
3
4
5
6

PEPG

PEPG

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get PepGen Inc. Data in Excel

Get PepGen Inc. Data in Excel